About Barrier Therapeutics
Barrier Therapeutics is a Healthcare company based in Princeton (United States) founded in 2002, and was acquired by Stiefel in June 2008. Topical drugs for dermatology disorders were developed. Barrier Therapeutics has raised $78 million across 2 funding rounds from investors including J P Morgan, Kbc and Stiefel. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its legal entity is BARRIER THERAPEUTICS INC. Its competitors include Revance Therapeutics, Dermavant and Sol-Gel Technologies; 3 of its 3 listed competitors have raised funding.
Company details
Barrier Therapeutics was focussed on developing topical drugs for dermatology disorders. Its marketed products include Xolegel, a topical gel for seborrheic dermatitis; Vusion, an ointment for infants and children suffering from diaper dermatitis; and Solage, a solution for the solar lentigines. It was also developing Hyphanox for onychomycosis; Pramiconazole for onychomycosis, and skin and mucosal fungal infections; and Rambazole for psoriasis. In July 2008, it was acquired by Stiefel Laboratories for 148M.
- Headquarters Princeton, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website barriertherapeutics.com
- Social LinkedIn
- Acquired by Stiefel (Jun 2008)
- Legal Name Barrier Therapeutics Inc
- Total Equity Funding$78M (USD)
in 2 rounds
- Latest Funding Round$32M (USD), Series C
Oct 2003
- InvestorsJ P Morgan
& 5 more
- Acquired byStiefel
(Jun 2008)
Funding Insights of Barrier Therapeutics
Barrier Therapeutics has successfully raised a total of $78M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $32 million completed in October 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78M
- Total Rounds 2
- Last Round Series C — $32M
- First Round $46M
(May 2002)
- Investors Count 5
All 2 funding rounds of Barrier Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2003 | $32M | Series C | – | – | |
| May 2002 | $46M | Series B | – | – |
6 investors in total: 6 institutional.
Investors in Barrier Therapeutics
Barrier Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include J P Morgan, Kbc and Stiefel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Early-stage companies are invested in globally by TL Ventures. | tl.ventures | Wayne, United States | ||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Comprehensive financial services are provided to corporations and individuals. | 1799 | jpmorgan.com | New York, United States | |
Integrated bank-insurance group serving retail, private banking, and SME clients | kbc.com | Brussels, Belgium | ||
Dermatology prescription products are manufactured and marketed globally. | 1847 | stiefel.com | Durham, United States |
Investor details for Barrier Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Barrier Therapeutics
5 dated milestones of Barrier Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Barrier Therapeutics is founded.
- Funding First funding round of $46.0M.
- Funding Latest funding round, Series C, of $32.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Stiefel.
Competitors of Barrier Therapeutics
Barrier Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Dermavant and Sol-Gel Technologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| dermavant.com | 2016 | Phoenix, United States | $160M | Small molecule therapeutics for inflammatory skin diseases are developed. | ||
| sol-gel.com | 1998 | United States | $9M | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. |
Detailed competitors of Barrier Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Barrier Therapeutics (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Barrier Therapeutics
Barrier Therapeutics was founded in 2002.
Barrier Therapeutics is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Barrier Therapeutics is a funded company, having raised a total of $78M across 2 funding rounds to date. The company's 1st funding round was a Series B of $46M, raised on May 2002.
Barrier Therapeutics was focussed on developing topical drugs for dermatology disorders. Its marketed products include Xolegel, a topical gel for seborrheic dermatitis; Vusion, an ointment for infants and children suffering from diaper dermatitis; and Solage, a solution for the solar lentigines. It was also developing Hyphanox for onychomycosis; Pramiconazole for onychomycosis, and skin and mucosal fungal infections; and Rambazole for psoriasis. In July 2008, it was acquired by Stiefel Laboratories for 148M.
Barrier Therapeutics's top competitors include Revance Therapeutics, Dermavant and Sol-Gel Technologies.
Barrier Therapeutics has 6 investors. Key investors include J P Morgan, Kbc, Stiefel, Turmeric Acquisition Corp, and Johnson & Johnson Innovation – JJDC.
Barrier Therapeutics operates through Barrier Therapeutics Inc.
Yes. Barrier Therapeutics was acquired by Stiefel in June 2008.